Stage IV Non-Small Cell Lung Cancer without Driver Alterations
Key Points
Key Points
This clinical practice guideline update addresses two overarching clinical questions:
- What are the most effective first-line treatment options for patients with stage IV NSCLC without driver alterations, based on cancer subtype?
- What are the most effective second-line and subsequent treatment options for patients with stage IV NSCLC without driver alterations based on cancer subtype?
Treatment
...atment...
...For recommendations with multiple treatm...
...tion 1: What are the most effective first-line tr...
...mous Cell Carcinoma (Non-SCC)...
...ients with programmed death-ligand 1 or progr...
...patients with a programmed death-ligand 1 or...
...For patients with a programmed deat...
...patients with a programmed death-ligand 1...
...ients with a programmed death-ligand...
...ts with a programmed death-ligand 1...
...tients with a programmed death-ligand 1 o...
...PD-L1 expression TPS, 1–49%:...
...ients with PD-L1 expression TPS, 1–49%,...
1.8. For patients with PD-L1 expression TP...
...s with PD-L1 expression TPS, 1–49%, clinicians...
...patients with PD-L1 expression TPS, 1...
...For patients with PD-L1 expression...
...tients who are ineligible for or decline the...
...with unknown or negative PD-L1 expression, TP...
...For patients with unknown or negative...
...s with unknown or negative PD-L1 expression, TP...
...For patients with unknown or negative PD-L1...
...ents with unknown or negative PD-L1 exp...
...nts with unknown or negative PD-L1 exp...
Squamous Cell Carcinoma (SCC)
...ts with PD-L1 expression, TPS...
.... For patients with PD-L1 expressio...
...r patients with PD-L1 expression, TPS...
...nts with PD-L1 expression, TPS ≥50%, clini...
...tients with PD-L1 expression, TPS â...
...ients with PD-L1 expression, TPS ≥50%, clinicia...
...ients with PD-L1 expression TPS, 1–...
...s with PD-L1 expression TPS, 1–49%, clinicians...
...ients with PD-L1 expression TPS, 1–49%,...
...or patients with PD-L1 expression TPS...
...tients with PD-L1 expression TPS, 1–49%, cli...
...ients with PD-L1 expression TPS, 1–49% who ar...
...with unknown or negative PD-L1 ex...
...1. For patients with unknown or negative...
...or patients with unknown or negative...
...ients with unknown or negative PD-L1 expre...
4.4. For patients with unknown or negative PD...
...with Unspecified Histolog...
4.5. For patients with unknown or negative P...
...s with unknown or negative PD-L1 exp...
...r patients with unknown or negative PD-L1...
...cizumab should be avoided for patients with squamo...
...with contraindications to bevacizumab:...
...atients with Unspecified Hist...
...izumab should be avoided for patient...
...ntenance bevacizumab given with pemetrexed...
...ion 2: What are the most effective s...
...nts previously treated with immune checkpoint...
...For patients previously treated with imm...
...viously treated with chemotherapy and immune...
...n patients previously treated with chemotherap...
.... In patients previously treated with chem...
...nd-Line and Subsequent Treatment Options for Patie...
...st-Line Treatment Options for Patients With...
.... First-Line Treatment Options for Pa...